Allogeneic Transplantation
Leukemia Trials (AML & ALL)
COMIRB: 24-0178
Mitoxantrone for Venetoclax-Resistant Acute Myeloid Leukemia
Principal Investigator: Andrew Kent
Eligibility: Ages 鈮 18; Subject must have confirmation of non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)
COMIRB: 23-0273
Study of cladribine+venetoclax After Failure of venetoclax+hypomethylating Agent in Monocytic AML
PI: Christine McMahon
Eligibility: Ages 鈮 18 years; R/R AML; ECOG of 鈮2
COMIRB: 23-2063
Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
PI: Christine McMahon
Eligibility: acute leukemia; not eligible for participation in an ongoing clinical study and have no approved treatment options.
COMIRB: 23-0061
KO-MEN-007, Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia
PI: Christine McMahon
Eligibility: Ages 鈮 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of 鈮2
COMIRB: 18-0709
Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (aged 18-59) with Acute Myeloid Leukemia
PI: Dan Pollyea
Eligibility: Ages 18-59; untreated AML; ECOG of 鈮2
COMIRB: 20-1319
CC-486 and Venetoclax for Acute Myeloid Leukemia
PI: Dan Pollyea
Eligibility: Ages 鈮 18 years; non-APL AML and at least one line of therapy; ECOG of 鈮 2
COMIRB: 20-1388
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine 卤 Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
PI: Dan Pollyea
Eligibility: Ages 鈮 18 years; Relapsed or refractory AML with myelomonocytic or monoblastic/monocytic differentiation and has failed treatment with available therapies known to be active for AML; Relapsed or refractory LILRB4high AML with myelomonocytic or monoblastic/monocytic differentiation and has failed treatment with available therapies known to be active for AML; Newly diagnosed high LILRB4 expression monocytic AML patients considered to be ineligible for standard induction therapy; ECOG of 鈮 2
COMIRB: 20-2350
A Phase 1 Open-Label Study Of KPT-9274 In Patients with Relapsed or Refractory Acute Myeloid Leukemia
PI: Dan Pollyea
Eligibility: Ages 鈮 18 years; non-APL AML who have not responded to or relapsed after at least one prior therapy and for whom no standard therapy that may provide clinical benefit is available; ECOG of 鈮 2
COMIRB: 23-2210
Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia 鈥淪COPE 鈥 Leukemia鈥
Site PI: Stacy Fischer, MD
Eligibility: high risk AML patients based on the following inclusion criteria: 鈥 Newly diagnosed with AML at the age of 60 or greater 鈥 Antecedent hematologic disorder (prior blood disorder before AML diagnosis) 鈥 Therapy-related disease (radiation / chemotherapy for another cancer before AML diagnosis) 鈥 Relapse AML or primary refractory AML 鈥 Patient鈥檚 AML went into remission and came back 鈥 Patient received AML treatment and did not go into remission
COMIRB: 21-3416
Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
PI: Christine McMahon
Eligibility: Ages 鈮 18 years; untreated non-acute promyelocytic leukemia (APL) AML with a bone marrow or peripheral blood blast count 鈮20%; must be willing to undergo a blood sample for RARA biomarker investigational assay testing with confirmed RARA-positive results prior to C1D8
COMIRB: 22-0054
Phase I Safety and Tolerability Trial of CD19 Directed CAR T Cells in Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission
PI: Marc Schwartz
Eligibility: Ages 鈮 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of 鈮2
COMIRB: 22-1050
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
PI: Christine McMahon
Eligibility: Ages 鈮 18 years; Active Acute Leukemia harboring MLL rearrangement or NPM1c mutation (Arm A, B); Active Acute Leukemia harboring MLL rearrangement, NUP98 rearrangement or NPM1c mutation (Arm C, D, E, F); R/R Acute Leukemia (Phase 1) R/R ALL/MPAL/AML with an MLLr translocation or AML with NPM1c (Phase 2), ECOG of 鈮 2
COMIRB: 22-1502
Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
PI: Marc Schwartz
Eligibility: Ages 鈮 18 years; diagnosed R/R B-ALL; B-ALL blast expressing CD22; , ECOG of 0 or 1
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.